Pfizer (NY:PFE)

Rigani Press Announces Barnes & Noble Book Signing for Dr. S. Yin Ho's Groundbreaking Book

December 12, 2025

Via PRLog

Topics Artificial Intelligence

Pfizer Declares First-Quarter 2026 Dividend

December 12, 2025

From Pfizer Inc.

Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. ↗

December 12, 2025

Keep your expectations in check.

Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term.

The Best Turnaround Stock to Invest $1,000 in Right Now ↗

December 12, 2025

As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more...

Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles

December 12, 2025

The Great Divergence: Investors Retreat from High-Flying Tech as Market Seeks New Equilibrium

Topics Artificial Intelligence Bonds Economy

December 11, 2025

The financial markets are witnessing a significant "Great Divergence" as investor sentiment pivots sharply away from the high-flying technology stocks that have dominated portfolios for years. As of...

The financial markets in late 2025 present a complex narrative, a tug-of-war between the long-reigning titans of growth and a resurgent, yet often overshadowed, cohort of value stocks. While the...

Topics Artificial Intelligence Economy Law Enforcement

Value Stocks Stage a Comeback Bid Amidst Persistent Growth Dominance

December 11, 2025

Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? ↗

Topics Artificial Intelligence ETFs Economy

December 11, 2025

Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings.

Via Stocktwits

Topics Artificial Intelligence Stocks

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

December 10, 2025

Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next.

Pfizer reports Phase 3 results showing Tukysa with trastuzumab and pertuzumab prolonged progression-free survival by 8.6 months in HER2+ metastatic breast cancer.

Topics Intellectual Property

Pfizer's Tukysa Combo Shows Strong PFS Benefit In Metastatic Breast Cancer ↗

December 10, 2025

Via Benzinga

Markets Brace for Anticipated Fed Rate Cut Amidst Shifting Economic Landscape

December 10, 2025

As December 2025 draws to a close, financial markets are holding their breath in anticipation of a pivotal Federal Reserve interest rate decision. Investopedia's analysis reveals a pervasive market...

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Topics Artificial Intelligence Bonds Credit Cards

December 10, 2025

From Pfizer Inc.

Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.

Down 50%, Should You Buy the Dip on Pfizer? ↗

December 09, 2025

Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest...

Topics Intellectual Property

Looking for the most active stocks in the S&P500 index on Tuesday? ↗

December 09, 2025

Via Chartmill

PFE Stock Gains In Premarket – What Is The Deal With Shanghai Fosun Pharma’s Unit About? ↗

December 09, 2025

Pfizer signed an exclusive global collaboration and licensing agreement with YaoPharma to develop YP05002, a small-molecule GLP-1 receptor agonist for chronic weight management.

Via Stocktwits

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

December 09, 2025

From Pfizer Inc.

U.S. Households Brace for Financial Headwinds Despite Steady Inflation, New York Fed Reports

December 08, 2025

New York, NY – December 8, 2025 – A recent report from the Federal Reserve Bank of New York (New York Fed) reveals a concerning trend: U.S. households are growing increasingly pessimistic about their...

Government Relations and Policy Professional Kimberly Pinter Joins Bracewell's Policy Resolution Group in Washington, DC

Topics Economy

December 08, 2025

Washington, D.C.--(Newsfile Corp. - December 8, 2025) - Bracewell LLP announced today that Kimberly J. Pinter has joined the firm's...

Via Newsfile

How Do Investors Really Feel About Pfizer Inc? ↗

December 08, 2025

Via Benzinga

Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar ↗

December 08, 2025

Market-based odds now show an 87% chance of a rate cut.

Via Stocktwits

Topics ETFs Economy Government

3 Cash-Producing Stocks with Exciting Potential

December 07, 2025

Free cash flow is one of the most reliable indicators of financial durability. These businesses not only generate cash but reinvest intelligently to sustain momentum.

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

December 06, 2025

From Pfizer Inc.

These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?

Do These 3 Healthcare Stocks Need a Checkup? ↗

December 05, 2025

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.

Topics Intellectual Property

Why Is Moderna (MRNA) Stock Rocketing Higher Today

December 05, 2025

Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.

Topics Economy

Curious about the most active S&P500 stocks in today's session? ↗

December 05, 2025

Via Chartmill

Is This Pharmaceutical Giant a Buy After a Major Acquisition? ↗

December 05, 2025

The rebound is well underway.

There is plenty to be wary of with this drugmaker, but there are also reasons to be optimistic.

Topics Death

2 Headwinds Facing Pfizer Stock Going Into 2026 ↗

December 05, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Topics Intellectual Property

3 Low-Volatility Stocks with Warning Signs

December 05, 2025

Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 11% to $25.67 per share while the index has gained 15.3%.

3 Reasons PFE is Risky and 1 Stock to Buy Instead

December 04, 2025